Vanguard Group Inc Lucid Diagnostics Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,127,278 shares of LUCD stock, worth $4.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,127,278

Previous 888,874 364.33%

Holding current value

$4.37 Million

Previous $1.32 Million 258.46%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$1.09 - $1.65 $3.53 Million - $5.34 Million	3,238,404 Added 364.33%	4,127,278 $4.75 Million
Q1 2025 May 09, 2025	BUY	$0.79 - $1.59 $259,087 - $521,454	327,959 Added 58.47%	888,874 $1.32 Million
Q1 2024 May 10, 2024	BUY	$0.81 - $1.52 $185,104 - $347,356	228,524 Added 68.75%	560,915 $454,000
Q4 2023 Feb 14, 2024	BUY	$1.16 - $1.54 $7,916 - $10,510	6,825 Added 2.1%	332,391 $468,000
Q3 2023 Nov 14, 2023	BUY	$1.17 - $1.65 $6,707 - $9,459	5,733 Added 1.79%	325,566 $380,000
Q2 2023 Aug 14, 2023	BUY	$1.28 - $1.78 $512 - $712	400 Added 0.13%	319,833 $444,000
Q4 2022 Feb 10, 2023	BUY	$1.21 - $2.27 $81 - $152	67 Added 0.02%	319,433 $434,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.45 $49,426 - $111,452	32,305 Added 11.25%	319,366 $489,000
Q2 2022 Aug 12, 2022	SELL	$1.73 - $3.44 $44,659 - $88,803	-25,815 Reduced 8.25%	287,061 $649,000
Q1 2022 May 13, 2022	BUY	$2.85 - $5.24 $181,507 - $333,719	63,687 Added 25.56%	312,876 $1.05 Million
Q4 2021 Feb 14, 2022	BUY	$4.87 - $11.76 $1.21 Million - $2.93 Million	249,189 New	249,189 $1.34 Million

Others Institutions Holding LUCD

# of Institutions

Shares Held

15.2M

Call Options Held

Put Options Held

View Full List

About Lucid Diagnostics Inc.

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $40.9M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

More about LUCD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Lucid Diagnostics Inc. Transaction History